https://www.selleckchem.com/pr....oducts/Trichostatin-
BACKGROUND Condoliase is a novel, potent chemonucleolytic drug available for clinical use for lumbar disc herniation (LDH) in Japan. The aim of this study was to assess the clinical outcome of condoliase therapy in patients with LDH, as well as factors affecting the clinical outcome. METHODS We enrolled patients with LDH who were receiving condoliase injection. The following baseline data were collected symptom duration; herniation level and type; T2 signal intensity of herniation; adverse events; rates of spondylolisthesis, post
Curtir
Comentario
Compartilhar
